ProPepMD
Tirzepatide – 3-Month Supply – 503A Compounded
Tirzepatide – 3-Month Supply – 503A Compounded
This product is available after consultation with a specialist.
An in-person consultation with a RELAX specialist is required to discuss this product. Availability depends on clinical suitability and any applicable prescription requirements.
5mg 5mg 5mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 5mg, 5mg and 5mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
5mg 5mg 10mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 5mg, 5mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
5mg 10mg 10mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 5mg, 10mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
Starter: 5mg, 10mg, 15mg/mL
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at Starter: 5mg, 10mg, 15mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
10mg 10mg 10mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 10mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
10mg 10mg 15mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 10mg and 15mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
10mg 15mg 15mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 15mg and 15mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
10mg 15mg 20mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 15mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
15mg 15mg 15mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 15mg and 15mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
15mg 15mg 20mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 15mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
15mg 20mg 20mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 20mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
Maintenance: 20mg, 20mg, 20mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 20mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
15mg 20mg 25mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 20mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
20mg 20mg 25mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 20mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
20mg 25mg 25mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 25mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
Maintenance: 25mg, 25mg, 25mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 25mg, 25mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
20mg, 25mg, 30mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 25mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
25mg 25mg 30mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 25mg, 25mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
25mg 30mg 30mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 25mg, 30mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
Maintenance: 30mg, 30mg, 30mg
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 30mg, 30mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.
Vial size listed by supplier 2 mL
Supplier availability · In stock
Share
